Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Invested Capital: 2021-2025

Historic Invested Capital for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $1.1 billion.

  • Krystal Biotech's Invested Capital rose 28.45% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 28.45%. This contributed to the annual value of $946.4 million for FY2024, which is 21.54% up from last year.
  • Latest data reveals that Krystal Biotech reported Invested Capital of $1.1 billion as of Q3 2025, which was up 9.34% from $1.0 billion recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Invested Capital ranged from a high of $1.1 billion in Q3 2025 and a low of $408.2 million during Q3 2021.
  • For the 3-year period, Krystal Biotech's Invested Capital averaged around $846.4 million, with its median value being $838.9 million (2024).
  • Its Invested Capital has fluctuated over the past 5 years, first fell by 12.02% in 2022, then soared by 63.26% in 2024.
  • Quarterly analysis of 5 years shows Krystal Biotech's Invested Capital stood at $593.6 million in 2021, then declined by 12.02% to $522.2 million in 2022, then skyrocketed by 49.10% to $778.6 million in 2023, then climbed by 21.54% to $946.4 million in 2024, then rose by 28.45% to $1.1 billion in 2025.
  • Its last three reported values are $1.1 billion in Q3 2025, $1.0 billion for Q2 2025, and $984.7 million during Q1 2025.